Summary
Stryker Corporation (SYK) reported strong financial performance for the second quarter and first half of 2023, driven by significant net sales growth across both its MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The company demonstrated robust top-line expansion, with total net sales increasing by 11.2% in the quarter and 11.5% year-to-date on a reported basis, translating to 11.9% and 12.9% growth in constant currency, respectively. This growth was primarily fueled by increased unit volumes across its businesses, with price increases contributing a smaller, though positive, portion. Profitability metrics also showed improvement. Gross profit margin increased to 63.7% in the second quarter from 62.9% in the prior year, reflecting favorable sales pricing, volume, and mix, partially offset by manufacturing and supply chain costs. Operating income saw a substantial increase, rising to $965 million (19.3% margin) in the quarter and $1,700 million (17.4% margin) year-to-date, up from $772 million (17.2% margin) and $1,219 million (13.9% margin) respectively in the prior year. Diluted earnings per share (EPS) reached $1.93 for the quarter and $3.47 for the six months, a notable increase from $1.72 and $2.56 in the comparable periods of 2022. The company also reported healthy cash flow from operations, underscoring its financial strength and operational efficiency.
Financial Highlights
51 data points| Revenue | $5.00B |
| Cost of Revenue | $1.81B |
| Gross Profit | $3.18B |
| R&D Expenses | $346.00M |
| SG&A Expenses | $1.71B |
| Operating Expenses | $2.22B |
| Operating Income | $965.00M |
| Net Income | $738.00M |
| EPS (Basic) | $1.95 |
| EPS (Diluted) | $1.93 |
| Shares Outstanding (Basic) | 379.70M |
| Shares Outstanding (Diluted) | 383.90M |
Key Highlights
- 1Net sales increased by 11.2% to $4.996 billion in Q2 2023 and by 11.5% to $9.774 billion for the first six months of 2023, compared to the prior year periods. Constant currency sales growth was even stronger at 11.9% and 12.9% respectively.
- 2Gross profit margin improved to 63.7% in Q2 2023 from 62.9% in Q2 2022, driven by favorable volume, mix, and pricing, despite increased manufacturing and supply chain costs.
- 3Operating income significantly increased to $965 million in Q2 2023 from $772 million in Q2 2022, with the operating margin expanding from 17.2% to 19.3%.
- 4Diluted earnings per share (EPS) rose to $1.93 in Q2 2023 from $1.72 in Q2 2022, and for the first six months, EPS increased to $3.47 from $2.56.
- 5The company completed the acquisition of Cerus Endovascular Limited for $289 million in cash, plus potential milestones, to bolster its Neurovascular business.
- 6Cash flow from operating activities was robust, increasing to $1,133 million for the first six months of 2023 from $732 million in the prior year.
- 7The company reported continued strength in its MedSurg and Neurotechnology segment, with sales up 12.2% in Q2, and Orthopaedics and Spine also showed solid growth of 9.9% in Q2.